Neovacs S.Aの時価総額
Neovacs S.Aの時価総額は何ですか。
Neovacs S.A.の時価総額は110.10M$です。
時価総額の定義は何ですか。
時価総額は、取引された会社の発行済株式の市場価値であり、一定期間のb株式に発行済株式数を掛けたものに等しい。
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
EURONEXTのセクタHealth Careにおける時価総額の企業と比べるNeovacs S.A
Neovacs S.Aは何をしますか。
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Neovacs S.Aと類似の時価総額
- Wah Wo Hldg Grp Ltdの時価総額は110.00M$です。
- John Hancock Investors Trustの時価総額は110.01M$です。
- Generation Miningの時価総額は110.02M$です。
- Landmark Bancorp Incの時価総額は110.05M$です。
- Kings Arms Yard VCT PLCの時価総額は110.09M$です。
- Proficient Alpha Acquisitionの時価総額は110.09M$です。
- Neovacs S.Aの時価総額は110.10M$です。
- AeroGrow Internationalの時価総額は110.19M$です。
- Urbanaの時価総額は110.21M$です。
- The Income & Growth VCTの時価総額は110.22M$です。
- Pioneer Globalの時価総額は110.26M$です。
- Legacy Acquisitionの時価総額は110.28M$です。
- Golden Resources Development Internationalの時価総額は110.28M$です。